Senti Biosciences Holdings, Inc. SNTI

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) Nasdaq

We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits. These gene circuits, which we created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Using gene circuits, our product candidates are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration.

Last close 0.33 2026-09-04
Market cap $10.4M 2026-06-30 share count
52-week range 0.33 - 2.88

Valuation FY2025 figures against the last close

P/S470.9x
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS-2.73

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Revenue $22.0K$0$2.0M$3.3M$2.3M
R&D $37.6M$34.4M$32.1M$28.1M$22.0M
SG&A $26.2M$26.4M$37.2M$38.2M$21.2M
Total operating expenses $68.8M$61.0M$95.3M$66.4M$43.2M
Operating income -$68.8M-$61.0M-$92.7M-$62.1M-$40.4M
Pre-tax income -$61.4M-$52.8M
Income tax $0$0
Net income -$61.4M-$52.8M-$71.1M-$58.2M-$55.3M
EPS, basic -2.73-12.03-16.01-2.23-19.00
EPS, diluted -2.73-12.03-16.01-2.23-19.00
Shares, diluted (wtd. avg.) $22.5M$4.6M$4.4M$26.1M$2.9M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents $16.4M$48.3M$39.4M$61.0M$59.3M$31.0M
Short-term investments $0$40.9M$0
Receivables $626.0K$483.0K
Total current assets $23.3M$59.0M$71.2M$102.6M$60.2M
Property, plant and equipment $12.9M$21.3M$25.3M$51.4M$12.4M
Total assets $51.2M$97.8M$119.5M$180.8M$96.7M
Accounts payable $2.9M$1.5M$1.2M$1.4M$5.2M
Total current liabilities $14.0M$13.1M$12.7M$18.1M$14.5M
Total liabilities $45.6M$47.1M$52.6M$53.5M$36.3M
Retained earnings -$358.6M-$297.1M-$244.3M-$173.3M-$115.1M
Total equity $5.6M$25.6M$66.9M$127.3M-$111.5M-$58.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Operating cash flow -$43.4M-$41.4M-$52.4M-$34.9M-$34.6M
Depreciation and amortisation $3.6M$3.8M$3.6M$1.4M$769.0K
Stock-based compensation $5.7M$1.8M$9.7M$16.4M$2.3M
Capital expenditure $196.0K$26.0K$12.0M$41.4M$5.5M
Investing cash flow -$184.0K$34.0K$30.1M-$82.0M-$5.5M
Financing cash flow $11.8M$53.7M$779.0K$118.6M$68.4M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028429.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $236.38B 30.7x 10.0%
GILD GILEAD SCIENCES, INC. $187.23B 22.3x 2.4%
MRNA Moderna, Inc. $58.11B -39.9%
RVMD Revolution Medicines, Inc. $45.01B
BIIB BIOGEN INC. $32.60B 25.1x 2.2%
SCNI Scinai Immunotherapeutics Ltd. $25.80B 99.2%
NBIX NEUROCRINE BIOSCIENCES INC $15.82B 33.3x 21.4%
EXEL EXELIXIS, INC. $14.62B 21.2x 7.0%